The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

In April, the CDC’s influential Advisory Committee on Immunization Practices recommended expanding RSV vaccination to ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The agency's website indicates HHS Secretary Robert F. Kennedy Jr. adopted the previous advisory panel's suggestion to expand access on June 25. AP also reports on FDA vaccine chief Vinay Prasad's ...

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season.

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

The FDA has given the green light to expand the use of Moderna's vaccine for the treatment of RSV, the virus that causes ...

HSS’ newly formed Advisory Committee on Immunization Practices voted 5-2 to recommend Merck’s respiratory syncytial virus monoclonal antibody drug and against an ingredient in some flu vaccines. The ...